肝细胞癌患者TACE术后血清FGFR1、VEGFA和IRX5水平变化及其与疗效的关系研究*

doi:10.3969/j.issn.1672-5069.2025.06.023

实用肝脏病杂志 ›› 2025, Vol. 28 ›› Issue (6): 890-893.doi: 10.3969/j.issn.1672-5069.2025.06.023

肝细胞癌患者TACE术后血清FGFR1、VEGFA和IRX5水平变化及其与疗效的关系研究^*

杨兰, 许诗杰, 包华鑫

226600 江苏省海安市人民医院检验科(杨兰);扬州大学医学院附属海安市中医院介入科(许诗杰);肿瘤科(包华鑫)

收稿日期:2024-12-19 出版日期:2025-11-10 发布日期:2025-11-13
通讯作者: 许诗杰,E-mail:15190805451@163.com
作者简介:杨兰,女,28岁,大学本科,技师。E-mail:18852856635@163.com
基金资助:
^*江苏省卫生健康委医学科研立项项目(编号:Z2023091)

Serum FGFR1, VEGFA and IRX5 level changes in patients with hepatocellular carcinoma after TACE treatment

Yang Lan, Xu Shijie, Bao Huaxin

Clinical Laboratory, Hai'an People's Hospital, Nantong 226600, Jiangsu Province, China

Received:2024-12-19 Online:2025-11-10 Published:2025-11-13

摘要/Abstract

摘要： 目的探讨经肝动脉化疗栓塞术(TACE)治疗的肝细胞癌(HCC)患者血清成纤维生长因子受体1(FGFR1)、血管内皮生长因子A(VEGFA)和易洛魁族同源盒基因5(IRX5)水平变化及其对治疗疗效的影响,为临床治疗应答和预后评估提供新的生物标志物。方法 2020年1月～2021年10月我院诊治的HCC患者80例,均接受TACE治疗,术后随访3年。采用ELISA法检测血清FGFR1、VEGFA和IRX5水平。应用受试者工作特征曲线(ROC)评估血清生物标志物水平预测疗效的效能。结果在治疗后3个月评估,获得客观缓解(OR)者45例,非OR者35例;OR组血清FGFR1、VEGFA和IRX5水平分别为(173.2±28.6)pg/ml、(79.3±17.2)pg/ml和(47.4±5.6)ng/ml,均显著低于非OR组【分别为(210.6±33.3)pg/ml、(103.4±19.3)pg/ml和(69.9±6.2)ng/ml,P<0.05】;ROC曲线分析表明,血清三种标志物水平联合预测疗效的AUC为0.969(95%CI:0.924～1.000),其敏感度为97.8%,特异度为97.1%;在随访36个月末,接受TACE治疗的80例HCC患者生存率为48.8%,其中OR组为80.0%,非OR组为8.6%,差异显著(P<0.05)。结论在TACE治疗HCC患者后监测血清FGFR1、VEGFA和IRX5水平可能有助于评估疗效和预后,值得深入研究。

关键词: 肝细胞癌, 肝动脉化疗栓塞术, 成纤维生长因子受体1, 血管内皮生长因子A, 易洛魁族同源盒基因5, 治疗, 预后

Abstract: Objective The purpose of this study was to investigate serumfibroblast growth factor receptor 1 (FGFR1), vascular endothelial growth factor A (VEGFA) and Irx homeobox 5 (IRX5) level changes in patients with hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE). Methods 80 HCC patients were encountered in our hospital between January 2020 and October 2021, and all underwent TACE and followed-up for 36 months. Serum FGFR1, VEGFA and IRX5 levels were measured by using ELISA. Receiver operating characteristic (ROC) curves were applied to assess the predictive performance of postoperative serum biomarker levels for prognosis. Results By three months after treatment, objective remission (OR) was obtained in 45 cases and non-OR was found in 35 cases; serum FGFR1, VEGFA and IRX5 levels in OR group after TACE were (173.2±28.6)pg/ml, (79.3±17.2)pg/mland (47.4±5.6)ng/ml, all significantly lower than [(210.6±33.3)pg/ml, (103.4±19.3)pg/ml and (69.9±6.2)ng/ml, respectively, P<0.05] in non-OR group; ROC analysis showed that the AUC was 0.969(95%CI:0.924-1.000), with the sensitivity of 97.8% and the specificity of 97.1% when the three serum markers combined to predict efficacy after TACE; by end of 36 month, the survival rate was 48.8%, with 80.0% in OR group and 8.6% in non-OR (P<0.05). Conclusion Surveillance of serum FGFR1, VEGFA and IRX5 levels after TACE treatment might help predict efficacy and prognosis of patients with HCC.

Key words: Hepatoma, Transarterial chemoembolization, Fibroblast growth factor receptor 1, Vascular endothelial growth factor A, Irx homeobox 5, Therapy, Survival

杨兰, 许诗杰, 包华鑫. 肝细胞癌患者TACE术后血清FGFR1、VEGFA和IRX5水平变化及其与疗效的关系研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 890-893.

Yang Lan, Xu Shijie, Bao Huaxin. Serum FGFR1, VEGFA and IRX5 level changes in patients with hepatocellular carcinoma after TACE treatment[J]. Journal of Practical Hepatology, 2025, 28(6): 890-893.

参考文献

[1] Foerster F, Gairing S J, Ilyas S I, et al. Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology, 2022, 75(6): 1604-1626.
[2] Papatheodoridi M, Tampaki M, Lok A S, et al. Risk of HBV reactivation during therapies for HCC: A systematic review. Hepatology, 2022, 75(5): 1257-1274.
[3] Milosevic I, Todorovic N, Filipovic A, et al. HCV and HCCtango—deciphering the intricate dance of disease: a reviewarticle. Int J Mol Sci , 2023, 24(22): 16048.
[4] Ioannou G N. Epidemiology and risk-stratification of NAFLD-associated HCC.J Hepatol, 2021, 75(6): 1476-1484.
[5] 袁振刚,叶胜龙.肝细胞癌系统治疗策略:现状和前景.中华肝脏病杂志,2024,32(6):565-571.
[6] Duan S L, Fu W J, Jiang Y K, et al. Emerging role of exosome-derived non-coding RNAs in tumor-associated angiogenesis of tumor microenvironment. Front Mol Biosci, 2023, 10: 1220193.
[7] Jia Q, Chu H, Jin Z, et al. High-throughput single-cell sequencing in cancer research. Signal Transduct Target Ther, 2022, 7(1): 145.
[8] Xie Y, Su N, Yang J, et al. FGF/FGFR signaling in health and disease.Signal Transduct Target Ther, 2020, 5(1): 181.
[9] Huang W, Li H, Yu Q, et al. LncRNA-mediated DNA methylation: an emerging mechanism in cancer and beyond. J Exp Clin Cancer Res, 2022, 41(1): 100.
[10] Geng X, Yuan J, Xu W, et al. YWHAB is regulated by IRX5 and inhibits the migration and invasion of breast cancer cells.Oncol Lett, 2024, 28(4): 469.
[11] 中国医师协会介入医师分会. 中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南. 中华肝脏病杂志,2019,27(3):172-181.
[12] Khanam A, Kottilil S. New therapeutics for HCC: Does tumor immune microenvironment matter.Int J Mol Sci, 2022, 24(1): 437.
[13] Yang C, Luo Y, Yang H, et al. Effects of early TACE refractoriness on survival in patients with hepatocellular carcinoma: a real-world study.J Hepatocell Carcinoma, 2022,34:621-631..
[14] Mäkinen N, Meyerson M. Genomic insights into the mechanisms of FGFR1dependency in squamous cell lung cancer.J Clin Invest, 2023, 133(21): e174171.
[15] Malchers F, Nogova L, van Attekum M H A, et al. Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.J Clin Invest, 2023, 133(21):654-659.
[16] Szymczyk J, Sochacka M, Chudy P, et al. FGF1 protects FGFR1-overexpressing cancer cells against drugs targeting tubulin polymerization by activating AKT via two independent mechanisms. Front Oncol, 2022, 12: 1011762.
[17] Salita T, Rustam Y H, Mouradov D, et al. Reprogrammed lipid metabolism and the lipid-associated hallmarks of colorectal cancer. Cancers (Basel), 2022, 14(15): 3714.
[18] Pietrobono S, Stecca B. Aberrantsialylation in cancer: Biomarker and potential target for therapeutic intervention? Cancers (Basel),2021,13(9):325-328.
[19] Zhu L, Dai L, Yang N, et al. Transcription factorIRX5 promotes hepatocellular carcinoma proliferation and inhibits apoptosis by regulating the p53 signalling pathway.Cell Biochem Funct, 2020, 38(5): 621-629.
[20] Nagel S, Meyer C. Normal and aberrant TALE-class homeobox gene activities in pro-B-cells and B-cell precursor acute lymphoblastic leukemia.Int J Mol Sci, 2022, 23(19): 11874.

肝细胞癌患者TACE术后血清FGFR1、VEGFA和IRX5水平变化及其与疗效的关系研究^*

Serum FGFR1, VEGFA and IRX5 level changes in patients with hepatocellular carcinoma after TACE treatment

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	姚羽, 宁波. 肝硬化门静脉血栓形成机制、自发性再通和抗凝治疗研究进展^*[J]. 实用肝脏病杂志, 2025, 28(6): 801-804.
[2]	李思思, 姜艳贞, 付兆媛. 中西医结合治疗肝纤维化研究进展与思考^*[J]. 实用肝脏病杂志, 2025, 28(6): 805-808.
[3]	华琪, 刘琼, 陈琦. 艾米替诺福韦治疗经恩替卡韦治疗的低病毒血症的慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 818-821.
[4]	蒋婵娟, 邵靖渊, 徐林. 艾尔巴韦/格拉瑞韦治疗慢性肾病合并慢性丙型肝炎患者疗效和安全性研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 822-825.
[5]	王超杰, 谢群, 姜海, 周宝勤, 杨亮. 3D方案治疗初始治疗的基因1b型慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 826-829.
[6]	李卉, 陶娅, 胥勋梅, 王金帆. 利拉鲁肽治疗NAFLD合并T2DM患者疗效及其对外周血单个核细胞NLRP3、Caspase-1和ASC水平的影响^*[J]. 实用肝脏病杂志, 2025, 28(6): 830-833.
[7]	郑慧慧, 王玉蓉, 徐婷. 血脂康联合阿托伐他汀治疗非酒精性脂肪性肝病合并高脂血症患者效果研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 834-837.
[8]	王美玲, 李洁, 刘娟, 孙婷婷. 司美格鲁肽联合非诺贝特治疗2型糖尿病合并非酒精性脂肪性肝病患者疗效初步研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 838-841.
[9]	高海娜, 梁盼, 高琳辉, 朱立影, 宋媛, 李印肖, 刘阳. 艾塞那肽联合二甲双胍治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效初步研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 842-845.
[10]	陈晓玲, 张盼盼, 付玉芳, 王静. 司美格鲁肽联合化痰祛瘀通络方治疗NAFLD合并T2DM患者临床疗效初步研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 846-849.
[11]	田巍巍, 孙佳琦, 陈恳, 黄亚彬, 李锋, 冯海娟. 标准免疫抑制疗法联合甘草酸二铵治疗自身免疫性肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 854-857.
[12]	黄晓黎, 沈杰. 恩替卡韦联合红外肝病治疗仪治疗乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 878-881.
[13]	李建林, 李娅, 郑秋然, 王燕. ¹²⁵I放射性粒子植入联合TACE治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 894-897.
[14]	田潭平, 杨定华, 宋新, 周旅, 周国超, 付华, 蔡融民, 彭鹏. TACE联合免疫和靶向综合治疗中晚期原发性肝癌患者临床效果研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 898-901.
[15]	郭健伟, 贾健峰, 阳春, 刘娜, 曾勇, 李齐刚. 多模态超声评估原发性肝癌微血管侵犯及对经肝动脉栓塞化疗治疗后肿瘤复发的影响^*[J]. 实用肝脏病杂志, 2025, 28(6): 902-905.